trending Market Intelligence /marketintelligence/en/news-insights/trending/X_e6EuRnnsyrk8V9cC7bfQ2 content esgSubNav
In This List

VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder

The U.S. Food and Drug Administration granted the fast-track designation to VistaGen Therapeutics Inc.'s nasal spray PH94B.

SNL Image

The company was evaluating PH94B as a treatment that is nonaddictive, nonsedating and can be taken as and when needed, VistaGen said, adding that the company is preparing for PH94B's phase 3 trials. The South San Francisco, Calif.-based biopharmaceutical company's treatment is aimed at treating social anxiety disorder.

Fast-track designation gives regulatory priority to treatments that show promise, including frequent meetings with the FDA and priority review of the marketing application.

VistaGen also has a depression medicine, called AV-101, which has failed two mid-stage studies.